The European Investment Bank (EIB) said it is lending up to €100 million to Swedish medical-technology company Elekta AB to advance treatments for a range of cancers and neurological diseases.

The EIB loan will support Elekta’s research and development work in radiotherapy, radiosurgery, brachytherapy and the software used to plan and deliver therapies.

Stockholm-based Elekta develops technologies to treat illnesses including brain tumours, breast cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer and essential tremor. The company’s radiotherapy treatments serve more than 2 million patients worldwide a year.

Elekta, which sells its products in more than 120 countries, operates in roughly 40 nations and has about 4,000 employees, plans to invest around €200 million in its research programme between 2026 and 2029.

Most of the work will take place in Sweden and the Netherlands, with the EIB loan covering up to half of the investments.

“Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here,” said EIB Vice-President Karl Nehammer. “This financing will support the next generation of cancer and neurological treatments.”

Elekta’s research programme includes new radiotherapy, radiosurgery and brachytherapy systems as well as software for treatment planning, workflow automation and precision delivery. The goal is to improve the accuracy and efficiency of treatments while helping healthcare providers treat more patients as demand for cancer care grows.

“As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision,” said Elekta Chief Financial Officer Klara Eiritz.

“This financing provides additional flexibility to support our long-term strategy and continued investments in innovation that improve clinical outcomes, operational efficiency and the patient experience.”